Galectin Therapeutics (GALT) Expected to Announce Earnings on Monday

Galectin Therapeutics (NASDAQ:GALT) is projected to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $36.32 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 9:30 AM ET.

Galectin Therapeutics Price Performance

Shares of NASDAQ GALT opened at $2.68 on Friday. Galectin Therapeutics has a 1 year low of $1.12 and a 1 year high of $7.13. The firm has a 50-day moving average of $2.99 and a 200 day moving average of $4.26. The stock has a market cap of $172.79 million, a P/E ratio of -4.54 and a beta of 0.98.

Wall Street Analysts Forecast Growth

GALT has been the topic of several recent analyst reports. HC Wainwright increased their target price on Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Galectin Therapeutics has an average rating of “Hold” and an average price target of $11.00.

Insider Activity

In other news, insider Khurram Jamil sold 21,446 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $3.65, for a total transaction of $78,277.90. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jack W. Callicutt sold 20,354 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $3.67, for a total value of $74,699.18. Following the sale, the chief financial officer owned 7,614 shares in the company, valued at $27,943.38. The trade was a 72.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 204,000 shares of company stock worth $787,433 over the last quarter. Insiders own 52.60% of the company’s stock.

Institutional Investors Weigh In On Galectin Therapeutics

Several large investors have recently added to or reduced their stakes in GALT. XTX Topco Ltd increased its holdings in Galectin Therapeutics by 226.6% during the second quarter. XTX Topco Ltd now owns 42,805 shares of the company’s stock valued at $90,000 after buying an additional 29,699 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Galectin Therapeutics in the fourth quarter valued at about $90,000. Mangrove Partners IM LLC acquired a new stake in Galectin Therapeutics in the 4th quarter worth approximately $78,000. Russell Investments Group Ltd. increased its position in shares of Galectin Therapeutics by 9,997.2% in the 4th quarter. Russell Investments Group Ltd. now owns 18,074 shares of the company’s stock valued at $75,000 after acquiring an additional 17,895 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Galectin Therapeutics in the third quarter valued at about $73,000. 11.68% of the stock is owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.